Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ConocoPhillips
COP
|
+$3.16B |
| 2 |
Merck
MRK
|
+$2.72B |
| 3 |
SLB Ltd
SLB
|
+$1.62B |
| 4 |
Target
TGT
|
+$1.6B |
| 5 |
General Mills
GIS
|
+$930M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$2.81B |
| 2 |
Blackrock
BLK
|
+$2.57B |
| 3 |
US Bancorp
USB
|
+$1.84B |
| 4 |
M&T Bank
MTB
|
+$808M |
| 5 |
Huntington Bancshares
HBAN
|
+$595M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.45% |
| 2 | Financials | 11.9% |
| 3 | Healthcare | 10.6% |
| 4 | Consumer Discretionary | 9.01% |
| 5 | Industrials | 8.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3276
Eton Pharmaceutcials
ETON
$1.26B
| $172K | ﹤0.01% |
13,247
+8
| +0.1% | +$121 |
|
3277
Black Diamond Therapeutics
BDTX
$103M
| $169K | ﹤0.01% |
109,224
| – | – |
|
3278
Delcath Systems
DCTH
$441M
| $167K | ﹤0.01% |
13,091
+114
| +0.9% | +$1.62K |
|
|
ARTV
3279
Artiva Biotherapeutics
ARTV
$564M
| $165K | ﹤0.01% |
54,881
+11,355
| +26% | +$61.3K |
|
3280
Ultralife
ULBI
$88.6M
| $163K | ﹤0.01% |
30,387
| – | – |
|
3281
Inovio Pharmaceuticals
INO
$69.1M
| $161K | ﹤0.01% |
98,495
+27,429
| +39% | +$55K |
|
|
ORKA
3282
Oruka Therapeutics
ORKA
$5.86B
| $160K | ﹤0.01% |
15,608
| – | – |
|
3283
LanzaTech
LNZA
$69.8M
| $158K | ﹤0.01% |
6,532
-176
| -3% | -$15.8K |
|
3284
374Water
SCWO
$38.8M
| $158K | ﹤0.01% |
46,363
-1,449
| -3% | -$6.41K |
|
3285
Actinium Pharmaceuticals
ATNM
$23.7M
| $157K | ﹤0.01% |
97,604
+25,511
| +35% | +$32.4K |
|
3286
TScan Therapeutics
TCRX
$50.3M
| $156K | ﹤0.01% |
112,941
| – | – |
|
3287
Stem
STEM
$51.9M
| $156K | ﹤0.01% |
22,203
+4,000
| +22% | +$46.3K |
|
3288
LiveOne
LVO
$57.3M
| $155K | ﹤0.01% |
22,108
| – | – |
|
3289
Telomir Pharmaceuticals
TELO
$80.5M
| $150K | ﹤0.01% |
46,406
| – | – |
|
3290
KULR Technology Group
KULR
$129M
| $150K | ﹤0.01% |
14,184
| – | – |
|
3291
Aemetis
AMTX
$108M
| $148K | ﹤0.01% |
85,177
| – | – |
|
|
CLPR
3292
Clipper Realty
CLPR
$44.3M
| $147K | ﹤0.01% |
38,207
+6,638
| +21% | +$27.9K |
|
|
IGMS
3293
DELISTED
IGM Biosciences
IGMS
| $144K | ﹤0.01% |
125,614
-32,229
| -20% | -$59.9K |
|
|
GBIO
3294
DELISTED
Generation Bio
GBIO
| $144K | ﹤0.01% |
35,644
-1,059
| -3% | -$7.44K |
|
3295
Mammoth Energy Services
TUSK
$137M
| $144K | ﹤0.01% |
70,674
| – | – |
|
3296
McEwen Inc
MUX
$1.19B
| $141K | ﹤0.01% |
18,707
+3
| +0% | +$23 |
|
3297
Caesarstone
CSTE
$82.3M
| $140K | ﹤0.01% |
57,766
+9,403
| +19% | +$35.2K |
|
3298
Barnes & Noble Education
BNED
$436M
| $133K | ﹤0.01% |
12,663
| – | – |
|
3299
Blue Ridge Bankshares
BRBS
$331M
| $132K | ﹤0.01% |
40,597
| – | – |
|
3300
ALX Oncology
ALXO
$261M
| $131K | ﹤0.01% |
211,051
-5,656
| -3% | -$6.79K |
|
Similar funds
Charles Schwab's Q1 2025 Portfolio in Review
As of Q1 2025, Charles Schwab held 3,548 positions worth $533B, down 1.7% from $542B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2025: portfolio turnover was 3.6%. Charles Schwab opened 55 new positions and exited 74, leaving the 3,548-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 24% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2025 buy was iShares Currency Hedged MSCI Eurozone ETF: 7,259,426 shares worth $283M.
- Charles Schwab added most to ConocoPhillips in Q1 2025, an estimated $3.16B increase.
- Charles Schwab's biggest Q1 2025 reduction was Pfizer, cutting an estimated $2.81B.
- Charles Schwab fully exited Brookfield in Q1 2025, selling an estimated $218M.
- Charles Schwab's ten largest holdings make up 20% of its $533B portfolio in Q1 2025.
- Charles Schwab opened 55 new positions and closed 74 in Q1 2025.
- Charles Schwab's portfolio value fell 1.7% quarter-over-quarter to $533B.
Based on Charles Schwab's 13F filing for Q1 2025, filed 9 May 2025.